ICU Medical (ICUI) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

ICUI Stock Forecast

ICU Medical stock forecast is as follows: an average price target of $190.50 (represents a 21.48% upside from ICUI’s last price of $156.82) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

ICUI Price Target

The average price target for ICU Medical (ICUI) is $190.50 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $198.00 to $183.00. This represents a potential 21.48% upside from ICUI's last price of $156.82.

ICUI Analyst Ratings

Buy

According to 4 Wall Street analysts, ICU Medical's rating consensus is 'Buy'. The analyst rating breakdown for ICUI stock is 0 'Strong Buy' (0.00%), 2 'Buy' (50.00%), 2 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

ICU Medical Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 15, 2024	Brett Fishbin	KeyBanc	$198.00	$180.30	9.82%	26.26%
Oct 14, 2024	Michael Toomey	Jefferies	$183.00	$178.72	2.39%	16.69%
Jun 17, 2024	Jayson Bedford	Raymond James	$135.00	$117.44	14.96%	-13.91%
Aug 09, 2022		Raymond James	$190.00	$188.10	1.01%	21.16%
Aug 08, 2022		Raymond James	$208.00	$179.63	15.79%	32.64%
May 10, 2022		Raymond James	$235.00	$201.17	16.82%	49.85%

The latest ICU Medical stock forecast, released on Oct 15, 2024 by Brett Fishbin from KeyBanc, set a price target of $198.00, which represents a 9.82% increase from the stock price at the time of the forecast ($180.30), and a 26.26% increase from ICUI last price ($156.82).

ICU Medical Price Target by Period

	1M	3M	12M
# Anlaysts	-	2	3
Avg Price Target	-	$190.50	$172.00
Last Closing Price	$156.82	$156.82	$156.82
Upside/Downside	-100.00%	21.48%	9.68%

In the current month, the average price target of ICU Medical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ICU Medical's last price of $156.82. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 15, 2024	KeyBanc	Overweight	Overweight	Hold
Oct 14, 2024	Jefferies		Hold	Initialise
Sep 12, 2024	Raymond James	Outperform	Outperform	Hold
Aug 08, 2024	Raymond James	Outperform	Outperform	Hold
Jun 21, 2024	Needham		Hold	Initialise
Aug 08, 2022	Raymond James	Outperform	Outperform	Hold
May 10, 2022	Raymond James	Outperform	Outperform	Hold
Feb 28, 2022	Raymond James	Outperform	Outperform	Hold

ICU Medical's last stock rating was published by KeyBanc on Oct 15, 2024. The company gave ICUI a "Overweight" rating, the same as its previous rate.

ICU Medical Financial Forecast

ICU Medical Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$587.86M	-	$549.31M	$568.65M	$578.01M	$597.86M	$561.00M	$543.12M	$340.52M	$336.06M	$321.68M	$318.05M	$320.45M	$318.57M	$303.38M	$328.61M	$315.52M	$307.47M
Avg Forecast	$639.00M	$624.00M	$624.00M	$590.00M	$613.00M	$600.00M	$600.00M	$569.00M	$593.86M	$574.60M	$556.64M	$552.25M	$562.98M	$565.75M	$565.20M	$561.13M	$578.77M	$565.00M	$559.93M	$553.17M	$319.90M	$314.30M	$305.87M	$300.90M	$295.33M	$284.70M	$276.70M	$296.30M	$295.70M	$291.17M
High Forecast	$643.74M	$628.63M	$628.63M	$594.38M	$617.55M	$604.46M	$604.46M	$573.23M	$607.76M	$576.93M	$560.77M	$556.35M	$566.10M	$569.95M	$569.40M	$565.30M	$583.06M	$565.00M	$559.93M	$553.17M	$319.90M	$314.30M	$305.87M	$300.90M	$295.33M	$284.70M	$276.70M	$296.30M	$295.70M	$291.17M
Low Forecast	$633.52M	$618.65M	$618.65M	$584.94M	$607.74M	$594.85M	$594.85M	$564.12M	$579.96M	$572.28M	$551.87M	$547.51M	$558.42M	$560.90M	$560.35M	$556.32M	$573.80M	$565.00M	$559.93M	$553.17M	$319.90M	$314.30M	$305.87M	$300.90M	$295.33M	$284.70M	$276.70M	$296.30M	$295.70M	$291.17M
# Analysts	1	1	1	1	1	1	1	1	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	4	6	4	4	7	4
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.04%	-	0.97%	1.01%	1.00%	1.06%	1.00%	0.98%	1.06%	1.07%	1.05%	1.06%	1.09%	1.12%	1.10%	1.11%	1.07%	1.06%

ICU Medical's average Quarter revenue forecast for Mar 24 based on 1 analysts is $552.25M, with a low forecast of $547.51M, and a high forecast of $556.35M. ICUI's average Quarter revenue forecast represents a -6.06% decrease compared to the company's last Quarter revenue of $587.86M (Dec 23).

ICU Medical EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	1	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	4	6	4	4	7	4
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$-12.18M	-	$2.76M	$75.18M	$7.41M	$68.79M	$-14.25M	$45.89M	$46.84M	$55.56M	$59.57M	$51.78M	$54.23M	$50.58M	$45.45M	$43.84M	$43.09M	$54.08M
Avg Forecast	$87.83M	$85.77M	$85.77M	$81.09M	$84.26M	$82.47M	$82.47M	$78.21M	$81.63M	$78.98M	$76.51M	$12.05M	$77.38M	$77.76M	$77.69M	$10.95M	$45.87M	$63.34M	$62.77M	$11.71M	$35.86M	$35.24M	$34.29M	$47.64M	$33.11M	$31.92M	$31.02M	$39.00M	$33.15M	$32.64M
High Forecast	$88.48M	$86.40M	$86.40M	$81.70M	$84.88M	$83.08M	$83.08M	$78.79M	$83.54M	$79.30M	$77.08M	$14.45M	$77.81M	$78.34M	$78.26M	$13.14M	$55.04M	$63.34M	$62.77M	$14.05M	$35.86M	$35.24M	$34.29M	$57.17M	$33.11M	$31.92M	$31.02M	$46.80M	$33.15M	$32.64M
Low Forecast	$87.08M	$85.03M	$85.03M	$80.40M	$83.53M	$81.76M	$81.76M	$77.54M	$79.71M	$78.66M	$75.85M	$9.64M	$76.75M	$77.09M	$77.02M	$8.76M	$36.69M	$63.34M	$62.77M	$9.37M	$35.86M	$35.24M	$34.29M	$38.11M	$33.11M	$31.92M	$31.02M	$31.20M	$33.15M	$32.64M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-0.16%	-	0.04%	6.87%	0.16%	1.09%	-0.23%	3.92%	1.31%	1.58%	1.74%	1.09%	1.64%	1.58%	1.47%	1.12%	1.30%	1.66%

1 analysts predict ICUI's average Quarter EBITDA for Sep 23 to be $77.76M, with a high of $78.34M and a low of $77.09M. This is 2717.45% upper than ICU Medical's previous annual EBITDA (Jun 23) of $2.76M.

ICU Medical Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	1	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	4	6	4	4	7	4
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-17.15M	-	$-9.93M	$-9.81M	$-15.54M	$-13.21M	$-7.47M	$-38.07M	$19.93M	$31.08M	$28.40M	$23.73M	$26.14M	$24.99M	$18.91M	$16.83M	$20.64M	$26.56M
Avg Forecast	$57.61M	$53.49M	$51.40M	$41.27M	$49.00M	$45.09M	$42.64M	$33.36M	$36.22M	$30.54M	$24.39M	$-38.27M	$29.14M	$33.85M	$39.10M	$-34.79M	$19.51M	$35.70M	$40.49M	$-37.21M	$40.09M	$43.83M	$40.00M	$21.83M	$36.83M	$31.87M	$30.25M	$14.98M	$39.76M	$39.44M
High Forecast	$58.16M	$54.00M	$51.89M	$41.67M	$49.47M	$45.52M	$43.06M	$33.68M	$37.69M	$30.61M	$24.62M	$-30.62M	$29.88M	$33.88M	$39.48M	$-27.83M	$23.41M	$35.70M	$40.49M	$-29.77M	$40.09M	$43.83M	$40.00M	$26.20M	$36.83M	$31.87M	$30.25M	$17.97M	$39.76M	$39.44M
Low Forecast	$56.96M	$52.89M	$50.82M	$40.81M	$48.45M	$44.59M	$42.17M	$32.99M	$34.75M	$30.47M	$24.12M	$-45.93M	$27.91M	$33.81M	$38.66M	$-41.75M	$15.61M	$35.70M	$40.49M	$-44.66M	$40.09M	$43.83M	$40.00M	$17.47M	$36.83M	$31.87M	$30.25M	$11.98M	$39.76M	$39.44M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-0.59%	-	-0.25%	0.28%	-0.80%	-0.37%	-0.18%	1.02%	0.50%	0.71%	0.71%	1.09%	0.71%	0.78%	0.63%	1.12%	0.52%	0.67%

ICU Medical's average Quarter net income forecast for Mar 22 is $-37.21M, with a range of $-44.66M to $-29.77M. ICUI's average Quarter net income forecast represents a -286.76% decrease compared to the company's last Quarter net income of $19.93M (Dec 21).

ICU Medical SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	1	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	4	6	4	4	7	4
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$154.62M	-	$150.90M	$152.57M	$142.93M	$153.45M	$158.75M	$153.21M	$81.46M	$74.81M	$73.92M	$72.39M	$73.55M	$70.85M	$67.24M	$72.31M	$70.65M	$65.88M
Avg Forecast	$154.31M	$150.68M	$150.68M	$142.47M	$148.03M	$144.89M	$144.89M	$137.40M	$143.41M	$138.76M	$134.42M	$154.04M	$135.95M	$136.62M	$136.48M	$140.03M	$79.77M	$135.34M	$134.13M	$149.77M	$76.63M	$75.29M	$73.27M	$66.60M	$70.75M	$68.20M	$66.28M	$64.32M	$70.83M	$69.75M
High Forecast	$155.45M	$151.80M	$151.80M	$143.53M	$149.13M	$145.96M	$145.96M	$138.42M	$146.76M	$139.32M	$135.42M	$184.84M	$136.70M	$137.63M	$137.50M	$168.04M	$95.72M	$135.34M	$134.13M	$179.72M	$76.63M	$75.29M	$73.27M	$79.92M	$70.75M	$68.20M	$66.28M	$77.18M	$70.83M	$69.75M
Low Forecast	$152.98M	$149.39M	$149.39M	$141.25M	$146.76M	$143.65M	$143.65M	$136.22M	$140.05M	$138.19M	$133.26M	$123.23M	$134.85M	$135.45M	$135.31M	$112.03M	$63.81M	$135.34M	$134.13M	$119.82M	$76.63M	$75.29M	$73.27M	$53.28M	$70.75M	$68.20M	$66.28M	$51.46M	$70.83M	$69.75M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.14%	-	1.11%	1.09%	1.79%	1.13%	1.18%	1.02%	1.06%	0.99%	1.01%	1.09%	1.04%	1.04%	1.01%	1.12%	1.00%	0.94%

ICU Medical's average Quarter SG&A projection for Mar 24 is $154.04M, based on 1 Wall Street analysts, with a range of $123.23M to $184.84M. The forecast indicates a -0.37% fall compared to ICUI last annual SG&A of $154.62M (Dec 23).

ICU Medical EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	1	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	4	6	4	4	7	4
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$-0.71	-	$-0.41	$-0.41	$-0.65	$-0.55	$-0.31	$-1.61	$0.94	$1.47	$1.34	$1.12	$1.24	$1.19	$0.91	$0.81	$1.00	$1.29
Avg Forecast	$2.36	$2.19	$2.10	$1.69	$2.00	$1.84	$1.75	$1.36	$1.48	$1.25	$1.00	$0.82	$1.19	$1.39	$1.60	$1.43	$1.56	$1.46	$1.66	$1.80	$1.64	$1.80	$1.64	$1.50	$1.51	$1.31	$1.24	$1.63	$1.63	$1.62
High Forecast	$2.38	$2.21	$2.12	$1.71	$2.02	$1.86	$1.76	$1.38	$1.54	$1.25	$1.01	$0.83	$1.22	$1.39	$1.62	$1.43	$1.58	$1.46	$1.66	$1.80	$1.64	$1.80	$1.64	$1.50	$1.51	$1.31	$1.24	$1.63	$1.63	$1.62
Low Forecast	$2.33	$2.16	$2.08	$1.67	$1.98	$1.82	$1.73	$1.35	$1.42	$1.25	$0.99	$0.81	$1.14	$1.38	$1.58	$1.43	$1.54	$1.46	$1.66	$1.80	$1.64	$1.80	$1.64	$1.50	$1.51	$1.31	$1.24	$1.63	$1.63	$1.62
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-0.60%	-	-0.26%	-0.29%	-0.42%	-0.38%	-0.19%	-0.89%	0.57%	0.82%	0.82%	0.75%	0.82%	0.91%	0.73%	0.50%	0.61%	0.80%

According to 1 Wall Street analysts, ICU Medical's projected average Quarter EPS for Mar 22 is $1.80, with a low estimate of $1.80 and a high estimate of $1.80. This represents a 91.49% increase compared to ICUI previous annual EPS of $0.94 (Dec 21).

ICU Medical Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
AKYA	Akoya Biosciences	$2.54	$4.83	90.16%	Buy
XRAY	DENTSPLY SIRONA	$19.19	$29.50	53.73%	Hold
ANGO	AngioDynamics	$9.26	$13.00	40.39%	Buy
HAE	Haemonetics	$82.07	$107.00	30.38%	Buy
ATRC	AtriCure	$31.50	$39.67	25.94%	Buy
ATR	AptarGroup	$163.09	$200.00	22.63%	Buy
COO	Cooper Companies	$94.49	$115.00	21.71%	Buy
ICUI	ICU Medical	$157.17	$190.50	21.21%	Buy
MMSI	Merit Medical Systems	$99.00	$108.83	9.93%	Buy
NVST	Envista	$19.24	$20.29	5.46%	Hold
HOLX	Hologic	$72.26	$74.20	2.68%	Buy

ICUI Forecast FAQ

Is ICU Medical a good buy?

Yes, according to 4 Wall Street analysts, ICU Medical (ICUI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 50.00% of ICUI's total ratings.

What is ICUI's price target?

ICU Medical (ICUI) average price target is $190.5 with a range of $183 to $198, implying a 21.48% from its last price of $156.82. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will ICU Medical stock go up soon?

According to Wall Street analysts' prediction for ICUI stock, the company can go up by 21.48% (from the last price of $156.82 to the average price target of $190.5), up by 26.26% based on the highest stock price target, and up by 16.69% based on the lowest stock price target.

Can ICU Medical stock reach $200?

ICUI's average twelve months analyst stock price target of $190.5 does not support the claim that ICU Medical can reach $200 in the near future.

What are ICU Medical's analysts' financial forecasts?

ICU Medical's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.38B (high $2.4B, low $2.36B), average EBITDA is $327.4M (high $329.83M, low $324.59M), average net income is $170.09M (high $171.73M, low $168.19M), average SG&A $575.21M (high $579.48M, low $570.27M), and average EPS is $6.96 (high $7.03, low $6.88). ICUI's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2.48B (high $2.5B, low $2.46B), average EBITDA is $340.46M (high $342.99M, low $337.54M), average net income is $203.76M (high $205.72M, low $201.49M), average SG&A $598.15M (high $602.59M, low $593.02M), and average EPS is $8.34 (high $8.42, low $8.24).

Did the ICUI's actual financial results beat the analysts' financial forecasts?

Based on ICU Medical's last annual report (Dec 2023), the company's revenue was $2.26B, beating the average analysts forecast of $2.26B by 0.18%. Apple's EBITDA was $22.82M, missing the average prediction of $243.78M by -90.64%. The company's net income was $-29.655M, missing the average estimation of $67.3M by -144.07%. Apple's SG&A was $606.69M, beating the average forecast of $549.08M by 10.49%. Lastly, the company's EPS was $-1.23, missing the average prediction of $5.6 by -121.95%. In terms of the last quarterly report (Dec 2023), ICU Medical's revenue was $587.86M, beating the average analysts' forecast of $562.98M by 4.42%. The company's EBITDA was $-12.183M, missing the average prediction of $77.38M by -115.74%. ICU Medical's net income was $-17.147M, missing the average estimation of $29.14M by -158.84%. The company's SG&A was $154.62M, beating the average forecast of $135.95M by 13.73%. Lastly, the company's EPS was $-0.71, missing the average prediction of $1.19 by -159.54%